IRA Negotiation Impact on Part B Beneficiary OOP Costs | Avalere
Between 0.03% and 0.1% of Medicare FFS beneficiaries would experience lower OOP costs for the first 10 Part B drugs likely to be negotiated.| Avalere
Between 0.03% and 0.1% of Medicare FFS beneficiaries would experience lower OOP costs for the first 10 Part B drugs likely to be negotiated.| Avalere
The Inflation Reduction Act (IRA) is bringing landmark policy changes to the pharmaceutical and healthcare industries, raising important questions about drug pr| Avalere
The Inflation Reduction Act (IRA) is introducing landmark policy changes to the healthcare industry, raising important questions about launch prices, pipeline strategy, and evidence requirements. In the IRA Question of the Week series, Avalere answers the pressing questions shaping healthcare stakeholders’ strategic decision-making as the law is implemented. In this installment, Avalere experts discuss how orphan drug investment…| Avalere
Download the free vaccines eBook here. Since Dr. Edward Jenner’s development of the first smallpox vaccine in 1796, vaccines have revolutionized public health, saving at least 154 million lives globally over the past 50 years. Available vaccines now protect against more than 20 infectious diseases. The COVID-19 pandemic saw rapid development of vaccines using a…| Avalere
Payer marketing combines data and storytelling to communicate product value and differentiation and ensure patient access.| Avalere
